JP2013536837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536837A5 JP2013536837A5 JP2013527062A JP2013527062A JP2013536837A5 JP 2013536837 A5 JP2013536837 A5 JP 2013536837A5 JP 2013527062 A JP2013527062 A JP 2013527062A JP 2013527062 A JP2013527062 A JP 2013527062A JP 2013536837 A5 JP2013536837 A5 JP 2013536837A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- inhibitor
- disulfiram
- selegiline
- aldehyde dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical group CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 20
- 229960002563 disulfiram Drugs 0.000 claims 10
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 9
- 229960003946 selegiline Drugs 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 6
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims 4
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 3
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims 2
- 201000006145 cocaine dependence Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- KFUSIRMDWATCKL-UHFFFAOYSA-N 1-aminocyclopropan-1-ol Chemical compound NC1(O)CC1 KFUSIRMDWATCKL-UHFFFAOYSA-N 0.000 claims 1
- 229940097693 Aldehyde dehydrogenase inhibitor Drugs 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37909510P | 2010-09-01 | 2010-09-01 | |
| US61/379,095 | 2010-09-01 | ||
| PCT/US2011/001529 WO2012050594A1 (en) | 2010-09-01 | 2011-08-31 | Treatment for cocaine addiction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536837A JP2013536837A (ja) | 2013-09-26 |
| JP2013536837A5 true JP2013536837A5 (enExample) | 2014-09-25 |
| JP6355921B2 JP6355921B2 (ja) | 2018-07-11 |
Family
ID=45938591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527062A Expired - Fee Related JP6355921B2 (ja) | 2010-09-01 | 2011-08-31 | コカイン嗜癖の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130165511A1 (enExample) |
| EP (2) | EP3170499A1 (enExample) |
| JP (1) | JP6355921B2 (enExample) |
| KR (1) | KR20130132774A (enExample) |
| AU (3) | AU2011314358B2 (enExample) |
| CA (1) | CA2809966C (enExample) |
| DK (1) | DK2611440T3 (enExample) |
| PT (1) | PT2611440T (enExample) |
| WO (1) | WO2012050594A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| SG11201701995PA (en) | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| AU2018383098B2 (en) | 2017-12-11 | 2024-12-12 | Tonix Pharma Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| AU2020249868A1 (en) | 2019-03-26 | 2021-10-21 | Tonix Pharma Holdings Limited | Salt forms of S-(N, N-diethylcarbamoyl)glutathione |
| US11724486B2 (en) * | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155584A (en) | 1962-12-03 | 1964-11-03 | Abbott Lab | Compositions and method of inhibiting monoamine oxidase and treating hypertension |
| SE404186B (sv) | 1975-06-09 | 1978-09-25 | Astra Laekemedel Ab | Forfarande for framstellning av cyklopropanolderivat |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| US6319954B1 (en) | 1995-01-13 | 2001-11-20 | Somerset Pharmaceuticals, Inc. | S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions |
| BR9501972A (pt) | 1995-05-09 | 1997-08-26 | Tostes Luiz Roberto Mallat | Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo |
| AU709323B2 (en) | 1996-03-15 | 1999-08-26 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neuropathy by administering selegiline |
| US6255497B1 (en) | 1997-04-29 | 2001-07-03 | The Endowment For Research In Human Biology, Inc. | Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse |
| BR9814830A (pt) | 1997-10-28 | 2000-10-03 | Schering Corp | Método de redução de desejo em mamìferos |
| WO1999058124A1 (en) | 1998-05-12 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| WO2003037313A2 (en) * | 2001-10-31 | 2003-05-08 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| DK1441708T3 (da) * | 2001-11-05 | 2009-07-06 | Krele Pharmaceuticals Llc | Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| CA2414500A1 (en) * | 2002-12-17 | 2004-06-17 | Purepharm Inc. | Agonist-aversive combination medicines |
| US20080078382A1 (en) * | 2006-09-20 | 2008-04-03 | Lemahieu Edward | Methods and Systems of Delivering Medication Via Inhalation |
-
2011
- 2011-08-31 US US13/820,338 patent/US20130165511A1/en not_active Abandoned
- 2011-08-31 EP EP16204193.3A patent/EP3170499A1/en not_active Withdrawn
- 2011-08-31 CA CA2809966A patent/CA2809966C/en not_active Expired - Fee Related
- 2011-08-31 PT PT118328590T patent/PT2611440T/pt unknown
- 2011-08-31 WO PCT/US2011/001529 patent/WO2012050594A1/en not_active Ceased
- 2011-08-31 EP EP11832859.0A patent/EP2611440B1/en not_active Not-in-force
- 2011-08-31 JP JP2013527062A patent/JP6355921B2/ja not_active Expired - Fee Related
- 2011-08-31 DK DK11832859.0T patent/DK2611440T3/en active
- 2011-08-31 AU AU2011314358A patent/AU2011314358B2/en not_active Ceased
- 2011-08-31 KR KR1020137008187A patent/KR20130132774A/ko not_active Ceased
-
2016
- 2016-10-06 AU AU2016238908A patent/AU2016238908B2/en not_active Ceased
-
2018
- 2018-07-02 AU AU2018204813A patent/AU2018204813A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505282A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2010523587A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| JP2013155188A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2006504795A5 (enExample) | ||
| WO2008011426A3 (en) | Methods and medicaments for administration of ibuprofen | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| FI3746126T3 (fi) | Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi | |
| JP2015522630A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2013541583A5 (enExample) | ||
| JP2019515909A5 (enExample) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2016505050A5 (enExample) | ||
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении |